Research programme: RNA-targeted therapeutics - Ionis Pharmaceuticals/Roche
Latest Information Update: 06 Nov 2023
Price :
$50 *
At a glance
- Originator Ionis Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Huntington's disease
Most Recent Events
- 06 Oct 2023 Early research in Huntington's disease in USA (unspecified route)
- 27 Sep 2023 Ionis Pharmaceuticals and Roche collaborates for the development of RNA-targeted programs for Alzheimer's disease and Huntington's disease
- 27 Sep 2023 Early research in Alzheimer's disease in USA (unspecified route)